Diversified Consumer Services
Company Overview of University of Surrey
University of Surrey is an educational institution.
Guildford, GU2 7XH
Founded in 1991
Key Executives for University of Surrey
Deputy Vice-Chancellor of Research and Innovation
Compensation as of Fiscal Year 2015.
University of Surrey Key Developments
University of Surrey Announces 5G Innovation Centre
Sep 15 15
University of Surrey opened its 5G Innovation Centre (5GIC), securing the UK's role in leading the development of the next generation communications technology, 5G. Housing over 170 researchers and attracting over £70 million of investment, including £12 million from the Higher Education Funding Council for England (HEFCE), the 5GIC is large academic research centre dedicated to next generation mobile and wireless connectivity. The Centre brings together leading academic expertise and major industry partners to define and develop a global 5G network that will radically change lives across the world. Through their work, they have already developed a technology that enables speeds of one terabit per second (Tbps) - more than 1,000 times faster than the high 4G speed, and filed over 15 patents.
Eli Lilly and Company Announces Five-Year Research Partnership with University of Surrey
Dec 22 14
Eli Lilly and Company announced a five-year research partnership with the University of Surrey to study health outcomes, focusing on the effects of treatment in people with type 2 diabetes, which affects about 95% of those with the disease. Using real-world evidence (routine data gathered from patients undergoing diabetes treatments), Lilly and the University of Surrey will focus on developing answers to commonly asked clinical questions about the continuum of diabetes care, such as the role and timing of injectable therapy, factors impacting adherence to prescribed medicines and the pattern and rationale of therapy following diagnosis. Initially the Lilly-Surrey collaboration will focus on some key questions: Adherence to therapy: Why do some people follow their diabetes treatment plan while others do not? What role do healthcare providers play in improving adherence rates? What are the barriers and the long-term effects for those who do not adhere to their treatment? Triggers for initiation of injectable therapy: People with type 2 diabetes often transition to different therapies in an effort to gain greater control of the disease. These transitions could include moving from an oral treatment to an injectable medicine, such as a glucagon-like peptide 1 receptor agonist (GLP-1) or insulin. Which treatment would be best? What factors influence a health-care professional's decision in choosing an injectable option? What factors influence the patient's acceptance of that decision? Understanding perspectives of both the patient and healthcare professional: How can health-care providers gain a better understanding of the patient's journey? What are the key questions they and the patient can ask each other? Can real-world perspectives increase understanding of why some patients accept transition from orals to injectables to insulin, while others are less enthusiastic?.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
Most Searched Private Companies
Sponsored Financial Commentaries